NCT05171816 2026-03-11Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZenecaPhase 3 Active not recruiting110 enrolled 12 charts
NCT06909825 2026-03-05FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Fusion Pharmaceuticals Inc.Phase 2 Active not recruiting85 enrolled